VivaMed BioPharma teams up with Syngene International to fast-track AI-driven drug programmes
The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities
The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities
Expansion at the Oss (NL) site adds capacity and R&D capabilities, supporting the development and manufacturing of ADCs and other novel bioconjugates from First-in-Human to commercialization
The agreement ensures BIOEMTECH customers can consistently obtain Ac-225 for preclinical studies
Vanrafia, a potent endothelin A receptor antagonist, received accelerated approval in the US and China in 2025 for reducing proteinuria in adults with IgAN
The initiative, delivered in collaboration with Accenture, integrates digitally enabled operating models powered by advanced analytics and AI across the company’s procurement, manufacturing, and distribution networks
The collaboration is anchored in Syngene’s SynVent platform and Connector model to accelerate promising academic research
The company reported profit before tax of Rs.67 crore, up sharply from Rs.21 crore in the same period last year
The new OMR facility, located in Chennai’s medical hub, is close to leading hospitals and offers excellent road and air connectivity
Subscribe To Our Newsletter & Stay Updated